April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 21, 2025

Higher Dietary Acid Load Tied to Knee OA

“This study demonstrates a significant association between high DAL and increased odds of [knee] OA.”

Conexiant

April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 21, 2025

Key Risk Factors for Shoulder Pain

"Three of the five significant risk factors for injury can be identified by objective pre-screening measures."

Conexiant

April 18, 2025

Gout Remission Linked to Lower Urate, Fewer Flares

Remission in gout after urate-lowering therapy was seldom after 1 but high after 5 years, finds a five-year NOR-Gout study tracking 211 patients.

Conexiant

April 16, 2025

How Do Feet Beat the Stress?

"As the calcaneus grows in size, it becomes taller, wider, and relatively shorter—essentially, more cube-like—revealing nature’s quiet strategy to manage internal bone stress."

Conexiant

April 16, 2025

E-Cigs + Cigarettes: Worse Disease Odds

"There is a need to reassess the assumption that e-cigarette use provides substantial harm reduction across all cigarette-caused diseases, particularly accounting for dual use," warns a comprehensive meta-analysis.

Conexiant

April 08, 2025

Study Investigates Efficacy of Baricitinib Tapering

Most patients maintained control of disease activity after tapering baricitinib, according to the RA-BEYOND study.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant